Harpal Dhillon has over 20 years of experience across the pharmaceutical industry, public health, and academia, specialising in antimicrobial resistance (AMR) and the translation of biomedical innovation into sustainable patient access. A recognised leader in antibiotic stewardship and policy, Harpal has worked globally to align clinical evidence, regulatory strategy, and valuation frameworks for therapies in resource-constrained settings.
His extensive background includes contributing to the DRIVE-AB consortium on global antibiotic valuation and serving as the inaugural Chair of the Royal Pharmaceutical Society’s Expert Antimicrobial Group. Beyond AMR, he applies these insights to improve access and value recognition for rare diseases and speciality medicines where evidence and reimbursement are often misaligned.
Harpal holds a PhD from Aston University, focused on strategies to optimise antibiotic prescribing.